BTIG Reiterates Buy on Kestra Medical Techs, Maintains $32 Price Target

BTIG analyst Marie Thibault has reiterated a Buy rating on Kestra Medical Techs (NASDAQ: KMTS) and maintained a price target of $32 for the stock. This endorsement reflects confidence in the company's performance and potential for growth.